In November, I had decided to challenge the impasse over the availability of an effective, but unlicensed, medication for Lambert Eaton Myasthenic syndrome by writing an FP10 for the cheaper […]
In November, I had decided to challenge the impasse over the availability of an effective, but unlicensed, medication for Lambert Eaton Myasthenic syndrome by writing an FP10 for the cheaper […]